RxDoctor Payments Data

Annmarie Zimmermann, MD

Family Medicine · Olean, NYNPI 1578535258

Payments from drug & device makers

$564in general payments, 2019–2025

Across 18 payments — averaging $31.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$245
  • Vapotherm Inc$84
  • AbbVie$77
  • Novo Nordisk$61
  • Merck$30
  • Bayer$15
  • plus $52 from 4 others

What the payments were for

  • Food & beverage$564100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead4$245
Vapotherm Inc1$84
AbbVie2$77
Novo Nordisk4$61
Merck2$30
Bayer1$15
Pfizer1$14
GSK1$14
AstraZeneca1$13
Amgen1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$564 in reported general payments places this provider in the 55th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$1,639
Medicare patients
33
Services billed
45

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide32$29,702
EliquisApixaban34$24,001
TrulicityDulaglutide25$23,716
JardianceEmpagliflozin24$22,312
XareltoRivaroxaban16$14,642
JanuviaSitagliptin Phosphate14$9,348
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$8,556
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$8,399
Gabapentin90$1,754
Pregabalin25$1,605
Omeprazole106$1,523
Levothyroxine Sodium119$1,442
Atorvastatin Calcium156$1,354
Lisinopril152$1,220
Albuterol Sulfate HfaAlbuterol Sulfate32$1,184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$61$29,70232 claims
PfizerEliquis$14$24,00134 claims
MerckJanuvia$30$9,34814 claims
GSKTrelegy Ellipta$14$8,39911 claims
AbbVieSynthroid$77$85115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,321 family medicine providers in New York.

Other family medicine in Olean

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →